CSIMarket
 


Acadia Pharmaceuticals Inc   (ACAD)
Other Ticker:  
 

Acadia Pharmaceuticals Inc 's Quick Ratio

ACAD's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


In the wake of the increase in Current Liabilities in the third quarter 2023, Quick Ratio fell to 1.65 a new company low.

Within Major Pharmaceutical Preparations industry 323 other companies have achieved higher Quick Ratio than Acadia Pharmaceuticals Inc in third quarter 2023. While Quick Ratio total ranking has improved so far during the III Quarter 2023 to 1245, from total ranking in the second quarter 2023 at 1281.

Explain Quick Ratio?
How much Cash & cash equivalents ACAD´s has?
What are ACAD´s Current Liabilities?


ACAD Quick Ratio (Sep 30 2023)
III. Quarter
(Jun 30 2023)
II. Quarter
(Mar 31 2023)
I. Quarter
(Dec 31 2022)
IV. Quarter
(Sep 30 2022)
III. Quarter
Y / Y Current Liabilities Change 79.81 % 59.7 % 87.54 % 30.77 % 32.14 %
Y / Y Cash & cash equivalent Change -20.77 % -13.97 % -9.67 % -19.95 % -19.2 %
Quick Ratio MRQ 1.65 2 1.8 3.32 3.75
ACAD's Total Ranking # 1245 # 1281 # 1041 # 628 # 665
Seq. Current Liabilities Change 11.53 % -16.21 % 78.54 % 7.77 % -0.94 %
Seq. Cash & cash equivalent Change -7.85 % -6.82 % -3.35 % -4.53 % 0.05 %



Quick Ratio third quarter 2023 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 324
Healthcare Sector # 586
Overall Market # 1245


Quick Ratio Statistics
High Average Low
45.97 11.15 1.65
(Mar 31 2014)   (Sep 30 2023)




Financial Statements
Acadia Pharmaceuticals Inc 's Current Liabilities $ 210 Millions Visit ACAD's Balance sheet
Acadia Pharmaceuticals Inc 's Cash & cash equivalent $ 346 Millions Visit ACAD's Balance sheet
Source of ACAD's Sales Visit ACAD's Sales by Geography


Cumulative Acadia Pharmaceuticals Inc 's Quick Ratio

ACAD's Quick Ratio for the trailling 12 Months

ACAD Quick Ratio

(Sep 30 2023)
III. Quarter
(Jun 30 2023)
II. Quarter
(Mar 31 2023)
I. Quarter
(Dec 31 2022)
IV. Quarter
(Sep 30 2022)
III. Quarter
Y / Y Current Liabilities TTM Growth 79.81 % 59.7 % 87.54 % 30.77 % 32.14 %
Y / Y Cash & cash equivalent TTM Growth -20.77 % -13.97 % -9.67 % -19.95 % -19.2 %
Quick Ratio TTM 2.06 2.49 2.9 3.62 4.09
Total Ranking TTM # 3567 # 1016 # 348 # 3532 # 314
Seq. Current Liabilities TTM Growth 11.53 % -16.21 % 78.54 % 7.77 % -0.94 %
Seq. Cash & cash equivalent TTM Growth -7.85 % -6.82 % -3.35 % -4.53 % 0.05 %


On the trailing twelve months basis Due to increase in Current Liabilities in the III Quarter 2023 to $209.60 millions, cumulative Quick Ratio decreased to 2.06 below the Acadia Pharmaceuticals Inc average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 472 other companies have achieved higher Quick Ratio than Acadia Pharmaceuticals Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the second quarter 2023 from 1016 to 3567.

Explain Quick Ratio?
How much Cash & cash equivalents ACAD´s has?
What are ACAD´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 473
Healthcare Sector # 977
Within the Market # 3567


trailing twelve months Quick Ratio Statistics
High Average Low
35.03 11.27 2.06
(Sep. 30, 2014)   (Sep 30 2023)




Companies with similar Quick Ratio in the quarter ending Sep 30 2023, within Major Pharmaceutical Preparations Industry Quick RatioSep 30 2023 MRQ Cash & cash equivalentSep 30 2023 MRQ Current Liabilities
Spyre Therapeutics Inc   4.54 $ 203.599  Millions$ 44.872  Millions
Immunogen inc   4.50 $ 605.535  Millions$ 134.660  Millions
Legend Biotech Corporation  4.43 $ 1,277.713  Millions$ 288.531  Millions
Corvus Pharmaceuticals Inc   4.41 $ 32.168  Millions$ 7.299  Millions
Lipella Pharmaceuticals Inc   4.39 $ 2.410  Millions$ 0.549  Millions
Cervomed Inc   4.23 $ 10.425  Millions$ 2.464  Millions
Nurix Therapeutics Inc   4.21 $ 258.852  Millions$ 61.493  Millions
Capricor Therapeutics inc   4.20 $ 28.521  Millions$ 6.792  Millions
Protagenic Therapeutics Inc new  4.12 $ 5.273  Millions$ 1.280  Millions
Mirum Pharmaceuticals Inc   4.10 $ 306.030  Millions$ 74.664  Millions
United Therapeutics Corporation  4.09 $ 2,875.500  Millions$ 703.500  Millions
Homology Medicines Inc  4.08 $ 103.298  Millions$ 25.292  Millions
Zymeworks Inc   4.06 $ 295.406  Millions$ 72.847  Millions
Sarepta Therapeutics Inc   4.05 $ 1,733.542  Millions$ 428.249  Millions
Imunon Inc   4.00 $ 19.377  Millions$ 4.846  Millions
Arcus Biosciences Inc   4.00 $ 799.000  Millions$ 200.000  Millions
Cartesian Therapeutics Inc   3.99 $ 79.603  Millions$ 19.939  Millions
Tg Therapeutics Inc   3.97 $ 229.159  Millions$ 57.678  Millions
Y mabs Therapeutics inc   3.97 $ 86.571  Millions$ 21.812  Millions
Syros Pharmaceuticals Inc   3.95 $ 112.219  Millions$ 28.394  Millions
Immunome Inc  3.92 $ 90.641  Millions$ 23.111  Millions
Cyclerion Therapeutics Inc   3.89 $ 9.108  Millions$ 2.341  Millions
Harrow Inc   3.88 $ 73.875  Millions$ 19.029  Millions
Biohaven Ltd   3.87 $ 240.596  Millions$ 62.177  Millions
Zevra Therapeutics Inc   3.84 $ 83.426  Millions$ 21.714  Millions
Aclaris Therapeutics Inc   3.82 $ 103.052  Millions$ 27.010  Millions
Ardelyx Inc   3.79 $ 165.080  Millions$ 43.529  Millions
Deciphera Pharmaceuticals Inc   3.79 $ 339.075  Millions$ 89.458  Millions
Uniqure N v   3.78 $ 229.484  Millions$ 60.719  Millions
Kiniksa Pharmaceuticals ltd   3.76 $ 201.084  Millions$ 53.468  Millions

Date modified: 2023-11-04T20:24:41+00:00



Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com